Clinical Trial News and Research

RSS

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland.

27 Nov 2014

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists from Queen Mary University of London have made a breakthrough in developing a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years.

26 Nov 2014

Promethera Biosciences completes €25.33 million ($31.4 million) Series C fundraising

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, today announces the completion of its Series C fundraising round. The company has raised €25.33 million ($31.4 million), including €20.33 million in capital.

26 Nov 2014

Dry powdered measles vaccine triggers no adverse side effects in early human testing

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal Vaccine.

26 Nov 2014

FDA-approved therapy could be effective in older, African American patients with lung cancer

University of Cincinnati researchers have found in a phase-2 clinical trial that a Food and Drug Administration-approved therapy could be effective in treating both older and African American patients with advanced lung cancer who may not be candidates for chemotherapy.

26 Nov 2014

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

The University of Texas Medical Branch is part of a collaboration led by the Oak Crest Institute of Science that received a $20 million grant from the National Institutes of Health to develop a novel intravaginal ring capable of delivering powerful antiretroviral drugs to prevent the spread of sexually transmitted HIV in women. The total award to UTMB is approximately $2.5 million.

26 Nov 2014

Experimental anti-cancer drugs PF-04691502 and PD-0325901 excel against colorectal cancer models

Genes make proteins and proteins tell your body's cells what to do: one talks to the next, which talks to the next, and to the next. Like a game of telephone, researchers call these "signaling pathways". Abnormalities in these signaling pathways can cause the growth and survival of cancer cells. Commonly, mutations or rearrangements of genes in the MAPK signaling pathway create cancer's fast growth, and alterations in the PI3K signaling pathway allow cancer cells to survive into virtual immortality.

26 Nov 2014

PPMD, Santhera Pharmaceuticals collaborate to study Duchenne muscular dystrophy

Parent Project Muscular Dystrophy, the leading advocacy organization working to end Duchenne muscular dystrophy (Duchenne) and Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases, will collaborate on a benefit/risk study in Duchenne.

25 Nov 2014

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Isis Pharmaceuticals, Inc. announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children with spinal muscular atrophy (SMA).

25 Nov 2014

CHMP approves Victoza for use in adults with type 2 diabetes, moderate renal impairment

The Committee for Medicinal Products for Human Use today issued a positive opinion for the use of Victoza (liraglutide) in adults with type 2 diabetes and moderate renal impairment.

25 Nov 2014

ProMedica invests in early stage medical device company

ProMedica has invested in an early stage medical device company that is developing and commercializing innovative and cost-effective devices for treating common vascular diseases such as peripheral artery disease (PAD). Jobst Vascular Surgeon John Pigott, MD, founded the Sylvania-based company, VentureMed Group, and its first invention is already being used in clinical trials underway in Europe.

25 Nov 2014

Ohio State researchers study repetitive transcranial magnetic stimulation for stroke rehabilitation

Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.

25 Nov 2014

New cell therapy offers hope for patients with liver cirrhosis

Liver disease patients could be helped by a new cell therapy to treat the condition.

24 Nov 2014

Merck, NewLink Genetics sign exclusive worldwide license agreement for Ebola vaccine candidate

Merck, known as MSD outside the United States and Canada, and NewLink Genetics Corporation, announced today that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV (Ebola) vaccine candidate.

24 Nov 2014

Hydroxyurea therapy offers safe, effective disease management of SCA

Conclusive data show that hydroxyurea therapy offers safe and effective disease management of sickle cell anemia (SCA) and reduces the risk of stroke, prompting early termination by the National Heart Lung and Blood Institute of a key clinical trial studying the drug's efficacy.

23 Nov 2014

New drug shows promise against treatment-resistant non-small cell lung cancer

A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I/II clinical trial.

23 Nov 2014

Promising molecular diagnostic approach to endometriosis

Researchers at UC San Francisco have identified patterns of genetic activity that can be used to diagnose endometriosis and its severity, a finding that may offer millions of women an alternative to surgery through a simple noninvasive procedure.

21 Nov 2014

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP).

21 Nov 2014

Self-acupressure may be effective for treating constipation

About 19 percent of North Americans suffer from constipation, with the digestive condition being more common among women, non-whites, people older than 60, those who are not physically active and the poor.

21 Nov 2014

Model G: New patient hospital gown blends style and comfort

A new Detroit design is rolling off the assembly line in the Motor City in 2015, made with a cotton-poplin blend for comfort, color-coded trim for ease of use and - most importantly - a closed backside that finally offers patients more privacy and comfort in the hospital.

21 Nov 2014

Clinical Trial News and Research

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Promethera Biosciences completes €25.33 million ($31.4 million) Series C fundraising

Dry powdered measles vaccine triggers no adverse side effects in early human testing

FDA-approved therapy could be effective in older, African American patients with lung cancer

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

Experimental anti-cancer drugs PF-04691502 and PD-0325901 excel against colorectal cancer models

PPMD, Santhera Pharmaceuticals collaborate to study Duchenne muscular dystrophy

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

CHMP approves Victoza for use in adults with type 2 diabetes, moderate renal impairment

ProMedica invests in early stage medical device company

Ohio State researchers study repetitive transcranial magnetic stimulation for stroke rehabilitation

New cell therapy offers hope for patients with liver cirrhosis

Merck, NewLink Genetics sign exclusive worldwide license agreement for Ebola vaccine candidate

Hydroxyurea therapy offers safe, effective disease management of SCA

New drug shows promise against treatment-resistant non-small cell lung cancer

Promising molecular diagnostic approach to endometriosis

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Self-acupressure may be effective for treating constipation

Model G: New patient hospital gown blends style and comfort

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer